Immatics and Editas join up to bring CRISPR to 'gamma delta' cell therapy

Editas Medicine will work with German immunotherapy maker Immatics to use CRISPR gene editing tools to boost the capabilities of an emerging type of cell therapy focused on gamma delta T cells, the companies announced Tuesday.